Phase IIb Multicenter Randomized Comparative Study of Anti-pneumococcal Vaccine Strategy in Patients Treated With Immunosuppressants or Biotherapies for Chronic Inflammatory Bowel Disease
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 104
- 试验地点
- 8
- 主要终点
- number of patients with anti-pneumococcal immunogenicity
研究概览
简要总结
This is a multicenter, prospective, randomized, open study comparing two anti-pneumococcal vaccination strategies in patients with Chronic Inflammatory Bowel Disease (CIBD) treated by immunosuppressants and/or biotherapies. At present such patients are poorly protected by anti-pneumococcal vaccination. In addition, vaccination efficacy in this type of patient is much weaker than in the general population. There are two types of anti-pneumococcal vaccines: firstly a polysaccharide, Pneumo23® (PSV-23®) vaccine and secondly a conjugate, Prevenar13® vaccine. New recommendations have just been issued by the HSCP advising immunocompromised patients to follow a vaccination plan combining one dose of Prevenar13® followed by one dose of PSV-23® after an interval of two months. In the case of young children infected with HIV, the recommendation is to multiply doses of Prevenar13® before the PSV-23® injection to improve vaccine efficacy in these immunocompromised patients.
Our study aims to identify an optimal vaccination strategy for immunocompromised CIBD patients by combining use of a conjugate vaccine, Prevenar13® and a polysaccharide vaccine, PSV-23®. We will compare the use of one or two doses (M0 +/- M2) of Prevenar13® combined with a later PSV-23® injection (M4) on vaccination immunogenicity measured by antibody titer against at least nine of the thirteen pneumococcal serotypes contained in Prevenar13®. We also want to evaluate the immunological impact of these different strategies in their capacity to stimulate a memory B anti-pneumococcal response more effectively. With this aim, we are studying all immunological functional aspects of the antibodies and B lymphocytes induced by the two vaccine strategies.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient who have given their written consent in a free and informed consent
- •Patient followed for inflammatory bowel disease (Crohn's disease, ulcerative colitis or indeterminate colitis), and treated for at least 3 months by immunosuppressive therapy and /or biotherapies and in clinical remission for at least 3 months
- •Patient agreeing to participate in the study throughout its duration and accepting the procedures related to the study
- •Contraception that the investigator judges effective for the first 12 months of the trial, with a negative pregnancy test
- •Women not planning to become pregnant in the 12 months following inclusion (M0)
- •Patient with social coverage
排除标准
- •Patients vaccinated against pneumo23 for less than 5 years
- •Other vaccination during the month before inclusion
- •Patient develops a febrile illness (at least 37 ° C 5 measured orally) or acute infection in the week before vaccination
- •The patient has a flare up of IBD the day of vaccination (Harvey-Brasdshaw score of at least 6 or CDAI > 220 for Crohn's disease or Mayo Clinic score of at least 4 for UC and indeterminate colitis)
- •Patients with an ongoing pregnancy the day of vaccination
- •Patient with a known history of neuropathy as Guillain-Barré syndrome.
- •Patients with known infection with HIV and / or HBV (HBsAg positive) and / or HCV
- •Patient with other severe immune deficiency
- •Patients who received immunoglobulin infusions of blood products, or of monoclonal antibodies (except anti-TNF) in the 3 months prior to vaccination
- •Patient institutionalized, or deprived of liberty administrative or judicial
- •Patients treated without immunosuppressive therapy or biotherapies
研究组 & 干预措施
1 dose Prevenar13 and 1 dose PSV23
one dose of the polysaccharide vaccine, Prevenar 13 at M0 and one dose of polysaccharide vaccine, Pneumo 23 at M4
干预措施: Prevenar 13 (Biological)
2 doses Prevenar13 and 1 dose PSV23
one dose of the polysaccharide vaccine, Prevenar 13 at M0, one dose of the polysaccharide vaccine, Prevenar 13, at M2 and one dose of polysaccharide vaccine, Pneumo 23 at M4
干预措施: Pneumo 23 (Biological)
2 doses Prevenar13 and 1 dose PSV23
one dose of the polysaccharide vaccine, Prevenar 13 at M0, one dose of the polysaccharide vaccine, Prevenar 13, at M2 and one dose of polysaccharide vaccine, Pneumo 23 at M4
干预措施: Prevenar 13 (Biological)
1 dose Prevenar13 and 1 dose PSV23
one dose of the polysaccharide vaccine, Prevenar 13 at M0 and one dose of polysaccharide vaccine, Pneumo 23 at M4
干预措施: Pneumo 23 (Biological)
结局指标
主要结局
number of patients with anti-pneumococcal immunogenicity
时间窗: month 5
Measured the serologies against serotypes to Prevenar 13. Serotype to be measured are 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A 19 F and 23F using the ELISA method
次要结局
- Number of patients with local and/or general reaction(Months 1, 3 and 5)
- Number of patients with inflammatory disease activity(Months 1, 3, 4, 5, 12, 18, 36)
- Factors implicated in anti-pneumococcal vaccination efficacy(Month 0)
- number of patients with serotype coverage of PSV-23(Months 5, 12, 18 and 36)